Overview of Dr. Rutherford
Dr. Sarah Rutherford is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from University of Virginia School of Medicine and has been in practice 8 years. She is one of 379 doctors at New York-Presbyterian Hospital and one of 117 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She has more than 30 publications and over 250 citings.
Office
520 E 70th St
Ste 341
New York, NY 10021Fax+1 646-962-1605
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2012 - 2015
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2009 - 2012
University of Virginia School of MedicineClass of 2009
Certifications & Licensure
NY State Medical License 2011 - 2026
PA State Medical License 2009 - 2012
Clinical Trials
- A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Start of enrollment: 2018 Sep 26
Publications & Presentations
PubMed
- 17 citationsTafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.David A Qualls, Nicholas Lambert, Paolo F Caimi, Mwanasha Merrill, Priyanka Pullarkat
Blood. 2023-12-28 - 17 citationsPhase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.Michael Dickinson, Javier Briones, Alex F. Herrera, Eva González-Barca, Nilanjan Ghosh
Blood Advances. 2021-11-23 - 4 citationsXPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.Rossella Marullo, Sarah C Rutherford, Maria V Revuelta, Nahuel Zamponi, Biljana Culjkovic-Kraljacic
Cancer Research. 2024-01-02
Journal Articles
- Extracellular Vesicles in DLBCL Provide Abundant Clues to Aberrant Transcriptional Programming and Genomic AlterationsSarah C Rutherford, Ashish Saxena, Rita Shaknovich, Blood
Abstracts/Posters
- Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)Sarah C. Rutherford, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO DatabaseSarah C. Rutherford, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Non-Destructive Post-Transplant Lymphoproliferative Disorder Shows Distinct Clinical Features with HHV-6 Reactivation in a SubsetSarah C. Rutherford, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
Major Eligibility Expansion Brings Moment of Truth for COVID Vaccines: Will Florida’s Young People Want Them?April 2nd, 2021
AI Therapeutics Announces That a Common LAM-002 Mechanism in Cancer and Neurodegenerative Diseases Shows Antitumor Activity in the Clinic and Hope for ALSJanuary 16th, 2020
LAM Therapeutics Announces Progress of Its Clinical Portfolio with FDA Clearance of New Trial in Leukemia and Advancement of Clinical Trial in LymphomaNovember 30th, 2017- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
